"anthem-biosciences"

Anthem Biosciences shares debuted with a 27% premium over the IPO price of ₹570, listing at ₹723 on Monday. The ₹3,395-crore IPO, subscribed 63.86 times, saw strong institutional interest. Anthem is a CRDMO specializing in complex fermentation-based APIs

The agreement with Anthem Biosciences is the second collaboration on 2-DG drug announced by IICT.